clinicians preference when semaglutide is not suitable for Weight Loss FAQ's Weight Loss Drug MET-097i vs Semaglutide: Ultra-Long-Acting vs

Novo Nordisks operating profits are up 58 percent since 2017, the year it introduced Ozempic, and sales of the GLP-1 agonists grew 42 percent last year, accounting for 98 percent of the companys overall growth

Pearls An Unusual Case of Non-ischemic Cardiomyopathy The diagnosis of drug-induced non-ischemic cardiomyopathy is usually one of exclusion

Long-term safety data shows GLP-1 receptor agonists are well tolerated, but ongoing monitoring with your provider is essential, especially if you continue treatment beyond one year

The loading phase, ~ 20 g per day for 5 to 7 days, is optional

However, some people on semaglutide have also reported getting yeast infections